Labrycor

Isoprenaline Hydrochloride, the active ingredient in Labrycor, is a beta‑adrenergic agonist presented as an intravenous solution for intravenous use. It stimulates heart rate and contractility and provides bronchodilation, making it useful in cardiac rhythm disorders and acute bronchospasm.

GNH USA supplies Labrycor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. This ensures consistent product availability across diverse markets.

Isoprenaline Hydrochloride acts on the cardiac and bronchial beta‑adrenergic pathways to restore rhythm and airway patency.

- Bradycardia: increases heart rate to maintain adequate cardiac output. - Heart block: enhances AV nodal conduction to improve rhythm. - Asystole: provides temporary cardiac stimulation until definitive therapy. - Asthma: relaxes bronchial smooth muscle to relieve bronchospasm. - Bronchospasm: induces bronchodilation for rapid airway opening.

Isoprenaline Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tachycardia: rapid increase in heart rate. - Palpitations: sensation of irregular heartbeat. - Headache: mild to moderate intensity. - Tremor: fine muscle shaking. - Nausea: occasional gastrointestinal upset. - Flushing: transient skin redness.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: marked drop in blood pressure. - Pulmonary edema: fluid accumulation in lungs.

When using Isoprenaline Hydrochloride, several precautions should be observed to ensure patient safety.

- Cardiac monitoring: continuous ECG and blood pressure assessment is required. - Dose titration: adjust infusion rate based on clinical response and hemodynamics. - Contraindications: avoid in patients with severe coronary artery disease or uncontrolled hypertension. - Drug interactions: review concomitant medications that affect adrenergic tone. - Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isoprenaline Hydrochloride can interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: antagonize therapeutic effects, may precipitate severe bradycardia. - Calcium channel blockers (non‑dihydropyridine): increase risk of conduction abnormalities. - MAO inhibitors: potentiate hypertensive responses.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte imbalances, affecting cardiac response. - Anticholinergic drugs: can modify heart rate response. - Tricyclic antidepressants: may enhance arrhythmic risk.